MSD Schweiz

MSD Merck Sharpe & Dohme AG employs over 1000 people working in local, regional and global functions across four sites in the canton of Lucerne and one site in the canton of Zurich. Our business activities are subdivided in the two divisions, Human Health and Animal Health.

MSD Human Health covers a broad range of biopharmaceuticals. Our areas of research and development are focusing on Oncology and Immuno-Oncology as well as vaccines to prevent diseases. In addition, MSD is conducting research in the area of infectious diseases to find new therapeutic approaches for antibiotic resistance, HIV/Aids and Hepatitis C and infections caused by bacteria or fungi. Further research focuses include immunology (auto-immune diseases) as well as cardio-metabolic diseases and Diabetes. MSD has a legacy in contributing to major public health challenges, such as River Blindness, Ebola and SARS-CoV-2.

MSD Animal Health develops and markets products for the prevention, treatment and control of disease in farm animals and pets. With the most innovative and largest product portfolio for animal health in Switzerland, MSD contributes substantially to animals’ well-being.

 

Our company has one of the largest clinical research programs worldwide. MSD Switzerland conducts 25 clinical trials per year for which the needed drugs are manufactured at our research and development site in Schachen. The Schachen site operates since 2018 one of the three MSD forensic laboratories worldwide, investigating in manipulations and counterfeiting of MSD products – an important contribution to patient safety.


The Swiss subsidiary of MSD Merck Sharpe & Dohme AG was founded in Lucerne in 1963. Our strong growth led to expansion and thus to the opening of additional sites in the canton of Lucerne. We are pleased that we are so well received as a company and that we can maintain an open and constructive dialogue with the business community, the canton and the city. Now it is time to consolidate our multiple office locations into a “One Roof concept”. We will achieve this in the emerging Rösslimatt district, which is scheduled for completion in 2025.
Franz Escherich
Swiss Hub Finance Operations Lead